Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The objective of this Investigation is to evaluate the safety and efficacy of Lyrica in
medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in
subjects treated with Lyrica will be monitored during the survey period, and whether an
additional treatment outcome investigation and/or a post-marketing clinical study is required
in the future will be determined.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.